Health Canada has approved CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions), a product from Johnson & Johnson's Janssen Pharmaceutical Companies, claimed to be the first and only once-monthly, long-acting regimen for the treatment of HIV-1 infection in adults, it was reported on Friday.
The product is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the present antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per millilitre [mL]). It is a co-packaged kit with two separate injectable medicines, Janssen's rilpivirine and ViiV Healthcare's cabotegravir.
The product was co-developed as part of a collaboration with ViiV Healthcare and is based on Janssen's 25-year commitment to make HIV history. ViiV Healthcare holds marketing authorisation for CABENUVA in Canada.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results